Neuroimaging of NMDA-sensitive Biomarkers in the Schizophrenia Spectrum

精神分裂症谱系中 NMDA 敏感生物标志物的神经影像学

• 批准号: 491177199
• 负责人: Professor Dr. Ulrich Ettinger
• 金额: --
• 依托单位: Klinik und Poliklinik für Psychiatrie und Psychotherapie
• 依托单位国家: 德国
• 项目类别: Research Grants
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/491177199?language=en
• 关键词: Neuroimaging; NMDA; sensitive; Biomarkers; Schizophrenia

The glutamate hypothesis is currently one of the most promising theories of the pathophysiology of schizophrenia. Despite intense research efforts into the role of glutamatergic dysfunction in schizophrenia and attempts to develop novel antipsychotic drugs that act on the glutamate system, very little is known about the role of glutamate in the wider spectrum of schizophrenia. Specifically, there is little evidence concerning the involvement of the glutamate system in schizotypy, the widely investigated subclinical expression of this dimensional disease phenotype. Additionally, no direct comparisons in schizophrenia biomarkers have been carried out so far between individuals under the influence of ketamine and patients with schizophrenia. Therefore, the present project has two major aims. First, it will investigate the effects of a subclinical, psychotomimetic dose of ketamine on perceptual-cognitive-motor behaviours and their underlying neural substrates using functional magnetic resonance imaging (fMRI) in people stratified by their level of schizotypy. Second, results from this study will be compared to results from schizophrenia patients, in order to delineate the boundaries of the glutamatergic basis of the schizophrenia spectrum.

谷氨酸假说是目前精神分裂症病理生理学最有前途的理论之一。尽管人们对谷氨酸能功能障碍在精神分裂症中的作用进行了大量研究，并尝试开发作用于谷氨酸系统的新型抗精神病药物，但人们对谷氨酸在更广泛的精神分裂症中的作用知之甚少。具体来说，几乎没有证据表明谷氨酸系统参与精神分裂，这是一种广泛研究的这种维度疾病表型的亚临床表达。此外，迄今为止，尚未在受氯胺酮影响的个体和精神分裂症患者之间进行精神分裂症生物标志物的直接比较。因此，本项目有两个主要目标。首先，它将使用功能磁共振成像（fMRI）对按精神分裂水平分层的人群研究亚临床拟精神病剂量的氯胺酮对知觉认知运动行为及其潜在神经基质的影响。其次，本研究的结果将与精神分裂症患者的结果进行比较，以描绘精神分裂症谱系的谷氨酸基础的边界。